GLP-1 RA have demonstrated significant cardiovascular protective effects, reducing the risk of major adverse cardiovascular events (MACE) in individuals with or at high risk for atherosclerotic cardiovascular disease (ASCVD), including those with T2DM [13]. Here, GLP1R is linked to type 2 diabetes mellitus.